Use of Magnetic Resonance Imaging In Multiple Sclerosis Trials Richard A. Rudick, M.D. Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland.

Slides:



Advertisements
Similar presentations
Defining suboptimal response to MS treatment: MRI outcome
Advertisements

Inflammation and Neurodegeneration in Multiple Sclerosis
Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Young Onset Neurodegeneration study. Neurology at the Memory Clinic Dr Thomas Monaghan SpR in Neurology Memory, Cognitive Studies and Behavioral Neurology.
© 2014 Direct One Communications, Inc. All rights reserved. 1 The Current Clinical Arena of Progressive Multiple Sclerosis Carrie M. Hersh, DO Mellen Center.
Multiple Sclerosis The Malaysian Saga Dr Rahul Chavan, MD Medical Director, Malaysia.
MSmcDESPOT: Follow-Ups November 1, Where We Are Baseline cross-section conclusions: – DVF is sensitive to early stages of MS where other measures.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
FREEDOMS II TRIAL.
Fingolimod Therapy for Multiple Sclerosis
Multiple Sclerosis: Clinical Treatment and Current Research Walter Royal, III, MD Associate Professor of Neurology Maryland Center for Multiple Sclerosis.
Multiple Sclerosis Jessica Kelly-Hannon It’s causes, effects and treatments.
Multiple Sclerosis (Definition)  “Multiple Sclerosis is a progressive demyelination of neurons in the central nervous system (the Brain and the Spinal.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
John M. Bertoni, M.D., Ph.D. Creighton University Multiple Sclerosis.
Composite MRI scores improve correlation with EDSS in multiple sclerosis by Poonawalla et al. Review by Jason Su.
Natalizumab use for neuropsychological deficits in relapsing multiple sclerosis K. Edwards, 1,2 W. Goodman, 1 1 MS Center of Northeastern New York (Latham,
Visualization of Fibers at Risk for Neuronal Tract Injury in Early MS by Streamtube Diffusion Tractography at 3 Tesla Jack H Simon 1 David E Miller 1 Mark.
Disease modifying drugs in MS Eva Havrdová Charles University, First Medical Faculty, Dpt. of Neurology Praha, Czech Republic.
© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.
Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.
Updates on Optic Neuritis Briar Sexton Neuro-ophthalmology Clinical Day Friday, November 18, 2005.
A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis Timothy L. Vollmer, MD Professor, Neurology and Neuroscience.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.
Laquinimod, a Once-Daily Oral Drug in Development for The Treatment of Relapsing–Remitting Multiple Sclerosis Stephen Krieger, MD Assistant Professor of.
Jalal Jalal Shokouhi-MD General secretary of Iranian society of Radiology
The Foundation Role of Immunomodulation Therapy for Long-Term Efficacy Safety, Outcome Measures, and Disability Mitigation Investigations Innovation Clinical.
Neuroimage Analysis Center An NCRR National Resource Center Time Series MRI Core Analysis, Modeling - toward Dynamic Surrogates.
conflicts of interest to report.
CMSC, June 2004 Inflammation and Secondary Progressive MS: Trials of Immunosuppression & Immunomodulators Ruth Whitham, MD James Bowen, MD VA MS Center.
Dennis Bourdette, MD VA MS Center of Excellence-West and
Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.
J OURNAL C LUB : S Magon, et al. University Hospital Basel, Switzerland “Label-Fusion-Segmentation and Deformation-Based Shape Analysis of Deep Gray Matter.
Fred D. Lublin, M.D. Corinne Goldsmith Dickinson Center for Multiple Sclerosis Icahn School of Medicine at Mount Sinai New York, NY, USA.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Large, Nonplateauing Relationship Between Clinical.
Ovarian age is associated with gray matter volume and disability in women with MS independent of chronological age and disease duration Jennifer Graves,
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Anti-CD25 Antibody Daclizumab in the Inhibition.
STUDY ON THE LEVELS OF TAU AND β-AMYLOID IN CSF OF PATIENTS WITH MULTIPLE SCLEROSIS Levente Szalárdy MD Department of Neurology University of Szeged Hungary.
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience.
In The Name of God. Multiple Sclerosis and Normal MRI new modalities for problems solving.
Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? R. Magliozzi, M. Calabrese, C. Cruciani,
Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease  C Bjartmar, J.R Wujek, B.D Trapp  Journal of.
MRI Evidence of Acute Inflammation in Cortical Gray Matter of Early Multiple Sclerosis Patients: Gadolinium Enhancing Cortical Lesions Josefina Maranzano,
Carrie M. Hersh, D.O., Robert Fox, M.D.
Comparison of cortical perfusion between relapse-remitting multiple sclerosis patients and healthy controls measured using Arterial Spin Labelling MRI.
Four Known Types of MS Clinically isolated syndrome (CIS)
NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.
GRAY MATTER ATROPHY IN PEDIATRIC MS PATIENTS
Multiple sclerosis: Oral Therapies and Beyond
Between-subject variability
Propensity Score Adjustment for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie M. Hersh, DO,1 Claire Hara-Cleaver,
Copyright © 2007 American Medical Association. All rights reserved.
Perspectives on Key MS Data From the Annual European MS Meeting
PPMI in the Medical Literature
What Predicts Disability Progression in Multiple Sclerosis?
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Volume 383, Issue 9936, Pages (June 2014)
Figure 1 The topographical model of multiple sclerosis, clinical (A) and subclinical (B) views The topographical model of multiple sclerosis, clinical.
Stephen L. Hauser, Jorge R. Oksenberg  Neuron 
Nat. Rev. Neurol. doi: /nrneurol
Volume 17, Issue 10, Pages (October 2018)
New Insights into Multiple Sclerosis Clinical Course from the Topographical Model and Functional Reserve  Stephen C. Krieger, MD, James Sumowski, PhD 
Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.
Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE) Kyle Smoot, MD, FAAN1, Kiren Kresa-Reahl, MD1, Pavle.
Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.
Presentation transcript:

Use of Magnetic Resonance Imaging In Multiple Sclerosis Trials Richard A. Rudick, M.D. Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic March 7, 2009

Conflict of Interest Statement Cleveland Clinic has accepted research funding from NIH (NINDS, NCRR), NMSS, Biogen Idec, and Nancy Davis Center Without Walls for my research I have accepted honoraria or consulting fees (< $10,000 per annum) from Biogen Idec, Millenium, Genzyme, Teva, and Novartis

Grant Support For Work Presented Today NIH PO1 NS38667 Project 3 and MRI/Pathology Core Pathogenesis of Multiple Sclerosis (Brain atrophy in multiple sclerosis) NIH RO1 NS38667; NMSS RG 3099 MSCRG Trial of IM IFN  -1a for RR-MS NMSS RG 3099 Brain atrophy in CIS NMSS PP0540 MS image analysis methodology Biogen Idec (BGEN 801) F/U of IFN  -1a study Nancy Davis Center Without Walls Clinical trial methodology

Outline of Talk MRI / Clinical Correlations Relapses / Disability Use of MRI in MS Trials Hot topics MRI Defined Rx Response Gray Matter Pathology

Multiple Sclerosis: Clinical Course SUBCLINICAL Preclinical Relapsing-RemittingSecondary Progressive Time  Disability  MS Relapses Progressive Disability (5-25 years)

MRI in Multiple Sclerosis Useful in diagnosis, management Used to test new treatments Provides insight into pathogenesis

Evolution of MS MRI lesions GAD T2 lesion Black Hole Richert N. unpublished (1998)

MRI in MS

FLAIR/T2: all “lesions” (edema, inflammation, demyelination, gliosis, axonal loss) Gad-enhancing: breakdown of blood-brain barrier, active inflammation T1 hypointense: axonal loss, severe tissue destruction MTR hypointense:demyelination, axonal loss

Low Correlation Between MRI Lesions and Relapses (SLC data) MRI lesions did not predict relapses in a multivariate model (n = 306); Held et al, Neurology 2005 : The project to validate MRI lesions as a relapse surrogate was stopped since the pre-requisite of correlation between MRI lesions and relapses was not met (n = 208); Petkau et al, Mult Scler 2008 : Retrospectice analysis of 31 placebo arms of RCT: no correlation between Gad lesions and relapses (n = 409) Daumer et al, Neurology 2009

Most lesions are clinically silent Kinetics (particularly as relates to disability) Low Correlation Between MRI Lesions and Relapses

Most lesions are clinically silent Kinetics (particularly as relates to disability) Low Correlation Between MRI Lesions and Relapses

Disease Activity Over 6.5 Years

If 90% Of New Lesions Are Subclinical, The Correlation Between New Lesions And Relapses Would Be 0.34

23 RCTs with MRI and relapse data Does the treatment effect on MRI lesions correlate with the treatment effect on relapses? A weighted linear regression was run Annals of Neurology, 2009, in press

log(REL effect) = log (MRI effect)

Validation with separate studies

In groups, the effect of a treatment on new lesions explains > 80% of the variance of the relapse treatment effect

Most lesions are clinically silent Kinetics (particularly as relates to disability) Low Correlation Between MRI Lesions and Relapses

SUBCLINICAL Preclinical Relapsing-RemittingSecondary Progressive Time  Disability  Variable (5-25 years) MRI Disability Or Atrophy Does MRI Predict Future Clinical Status?

Do MRI Lesions Predict Future Status?

Baseline T2 Lesion Load Predicts Disability at 5 Years Filippi et al. Neurology 1994; 44: % EDSS > 3.0

Brex et al. NEJM 2002:346; : EDSS < 3 EDSS > 3 SPMS Years from presentation T2 Lesion Volume BL 5 years 10 years 14 years T2 Lesion Growth In 5 Years Predicts Disability at 14 Years

Chard et al. JNNP 2003; 74: T2 Lesion Growth In 5 Years Predicts Brain Atrophy at 14 Years

Rudick et al. Ann. Neurol.2006;60: No correlation between T2 LL and future EDSS T2 Lesions In RRMS Predict Atrophy and Clinical Disability after 13 Years RRMS from Phase III trial (IFNB-1a)

BPF BPF = z = BPF = z = BPF = z = Healthy Controls (n=16) Mean +/- 2 SD Placebo Patients (n=72) Mean +/-SEM p < Baseline Year 1 Year 2 p = Brain Atrophy in the IM IFNβ-1a Clinical Trial (RRMS) Rudick, et al. Neurology 1999; 53:

% > EDSS 6.0 At F/U Brain Atrophy During The Trial Correlates With Disability At 8 Year F/U Fisher, et al. Neurology 2002 Quartiles of BPF  During 2 Year Clinical Trial

MRI Predicts EDSS > 6 SmallMedium Large Estimated Effect Size

MRI / Clinical Correlations (in RRMS) Lesions correlate with relapses in early MS Effect of intervention on lesions correlates strongly with relapse effect Lesions correlate with future disability and brain atrophy Brain atrophy during RR-MS correlates with future neurological disability

Natural History Of Multiple Sclerosis “BenignMS” Never Progresses Progressive Disability Threshold Amount Of CNS Injury “Typical MS” SP-MS Years After Onset “Severe MS” SP-MS After 5 Years Years After MS Onset

Outline of Talk UseMRI / Clinical Correlations Relapses / Disability MRI in MS Trials Hot topics MRI Defined Rx Response Gray Matter Pathology

MRI Parameters in MS Trials Gadolinium lesions are the primary outcome measure used to screen treatments Secondary outcome measures for registration trials  Gad lesions / T2 lesions  T1 holes / brain atrophy

Disease Modifying Drugs: Clinical and MRI Outcomes IM IFNb-1aSC IFNb-1a (44-µg) IFNb-1b (8-MIU) Glatiramer Acetate Relapse rate % reduction 32 p= p< p= p=0.007 Disability progression % reduction 37 p= p< p=NS 12 p=NS Number of Gd+ lesions % reduction 52 p= * p<0.001 NR 29* p= N/E T2 lesion number % reduction 33 p= p< p= * p<0.003 * = at 9 months

Disease Modifying Drugs: Clinical and MRI Outcomes IM IFNb-1aSC IFNb-1a (44-µg) IFNb-1b (8-MIU) Glatiramer Acetate Relapse rate % reduction 32 p= p< p= p=0.007 Disability progression % reduction 37 p= p< p=NS 12 p=NS Number of Gd+ lesions % reduction 52 p= * p<0.001 NR 29* p= N/E T2 lesion number % reduction 33 p= p< p= * p<0.003 * = at 9 months

Brain Atrophy in MS Trials Measured in nearly all trials (usually brain volume normalized to brain size) Issues  Slow rate of atrophy, short trial durations  Kinetic issues - fluid shifts and time course of neurodegeneration Multiple studies show reduced atrophy with anti-inflammatory therapies in RRMS No study has shown an atrophy effect in SPMS or PPMS

MRI Parameters in MS Trials Newer measures  Diffusion Tensor Imaging  Magnetic Resonance Spectroscopy  Magnetization Transfer Imaging  T1, T2 Relaxation Times  Functional MRI NYRFPT

Outline of Talk Use of MRI in MS Trials MRI / Clinical Correlations Relapses / Disability Hot Topics MRI Defined Rx Response GM Pathology

Original Avonex Study The 2-year cohort 167 patients Classification of responders Relapses in 2yr – cutoff 2 or more Gd+ lesions (yr 1 + yr2) – cutoff 2 or more New T2 at yr 2 (versus baseline)- cutoff 3 or more Outcome: EDSS, MSFC, BPF

EDSS Change In Responder Groups Based on T2 Lesions P=0.05 P=0.48 n=62 n=20 n=46 n=39 Rudick et al, Annals of Neurology 2004

P<0.01p=0.45 n=47 n=18 n=36 n=33 Rudick et al, Annals of Neurology 2004

Do Lesions During Initial 2 Years Predict Outcome (EDSS 6) At 15 Years?

n=30n=36 p = 0.03

n=30n=36 p = 0.59

n=32n=35 p = 0.04

n=32n=35 p = 1.0

AuthorResponder ClassificationResults Rudick Number of N/E T2 lesions at 2 yrs in PLC-controlled trial of IM IFNβ- 1a; Gad lesions at Yr 1 and pts studied for 2 years. > 3 new lesions predicted worse disease progression over 2 years; f/u at 15 years confirmed findings Pozzilli Gad lesions or new T2 lesions 1 year after beginning IFNβ 101 of 242 pts had MRI activity as defined. Higher likelihood of relapses in the 4-year observation (OR 3.6) Tomassini Gad lesions 1 year after beginning IFNβ; NAb while on IFN 68 patients followed for 6 years. Gad lesions predicted relapse or disability (OR 7.9); NAb associated with poor outcome (OR 7.3) Rio N/E T2 lesions or Gad lesions 1 year after starting IFNβ 152 pts studied for 2 years. >2 active lesions at 1 year was the primary factor predicting sustained EDSS progression (OR 8.3) Durelli Gad or T2 lesions 6 months after starging IFNβ; and IFNβ NAb during study 147 pts studied for 2 years. MRI lesions and/or NAb predicted relapse or sustained EDSS increase in the next 18 months KinkelGad or new T2 lesions 6 months after starting IFNβ in CIS 383 pts with CIS studied up to 2 years. Active MRI lesions predicted CDMS in IFNβ-1a but not placebo patients

Longitudinal studies consistently indicate that MRI activity while using IFNβ indicates patients with a relatively poor response to therapy and poor prognosis

Outline of Talk Use of MRI in MS Trials MRI / Clinical Correlations Relapses / Disability Hot Topics MRI Defined Rx Response GM Pathology

SPMS Cortical Pathology in MS Post-Mortem Studies > 90% of MS patients have cortical lesions (Lumsden 1970) Percentage of demyelinated area significantly higher in cortex than WM % vs. 6.5% (Bo, et al. 2003) Most cortical lesions are not detectable on conventional MRI (Geurts, et al. 2005) Kutzelnigg et al Brain 2005 Focal demyelinated WM plaque Cortical demyelination

Gray Matter Atrophy Segmentation of gray matter based on intensity and anatomic probability Gray matter fraction: GMF = GM volume / brain volume Provides estimate of overall amount of GM tissue damage Final GM AnatomicalGMT2w Nakamura and Fisher. NeuroImage 2009

Gray Matter Atrophy in Multiple Sclerosis: NIH Longitudinal Study 87 subjects followed over 4 years  17 controls  7 CIS  37 RRMS  26 SPMS Measured EDSS, MSFC, change in fractional brain volumes, lesion volumes, MTR Fisher, et al. Ann Neurol 2008

Atrophy Rates Relative to Healthy Controls Fisher, et al. Ann Neurol 2008

Gray Matter Atrophy Correlates with MS Disability Progression 87 subjects followed over 6.5 years  17 healthy controls  7 CIS  36 RRMS  27 SPMS Measured EDSS, MSFC, changes in fractional brain volumes Categorized patients as “progressed” or “stable” based on MSFC change over 6.5 years Rudick, et al. (JNNP 2009)

Rudick, et al. (JNNP 2008) Gray Matter Atrophy Correlates with MS Disability Progression

Gray Matter Pathology in MS Gray matter pathology increasingly dominates the pathology Gray matter atrophy correlates with disability progression Is MS a gray matter disease?

Outline of Talk MRI / Clinical Correlations Relapses / Disability Use of MRI in MS Trials Hot topics MRI Defined Rx Response Gray Matter Pathology

Future MRI Directions More specific MRI measures of MS pathology Imaging markers for GM pathology Use of MRI in neuroprotection trials Use of MRI to monitor / manage Rx

Collaborators

Biomedical Engineering: Elizabeth Fisher, Ph.D. Raghavan Gopalakrishnan, M.S. Patricia Jagodnik, B.S. Kunio Nakamura, B.S. Smitha Thomas, M.D. Bhaskar Thoomukuntla, M.S. Neurosciences: Angela Chang, M.D. Richard Ransohoff, M.D. Susan Staugaitis, M.D., Ph.D. Bruce Trapp, Ph.D. Radiology: John Cowan, R.T. Mark Lowe, Ph.D. Mike Phillips, M.D. Derek Tew, R.T. Mellen Center: Jeff Cohen, M.D. Bob Fox, M.D. Claire Hara-Cleaver, RN, NNP Dee Ivancic Lael Stone, M.D. Biostatistics: Jar-Chi Lee, M.S. Acknowledgements

Thank You For Your Attention